Vascular access complications · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Circuit lifespan · AKI patients receiving CKRT
1 finding from 1 review
no estimate extracted
1 study · 6 participants
Low
Death from any cause at day 28 of · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery of kidney function · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vascular access complications · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vascular access complications · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Circuit lifespana · AKI patients receiving CKRT
1 finding from 1 review
Death from any cause at day 28 of · AKI patients receiving CKRT
It is very uncertain whether CVVHDF changes death from any cause at day 28 of compared with CVVH (very low certainty).
1 finding from 1 review
Recovery of kidney function · AKI patients receiving CKRT
It is very uncertain whether CVVHDF changes recovery of kidney function compared with CVVH (very low certainty).
1 finding from 1 review
Vascular access complications · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse at 3 months · SSNS in children
Rituximab probably leads to lower relapses at 3 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
Mycophenolate mofetil showed no clear difference in frequent relapses at 12 months compared with levamisole (low certainty).
1 finding from 1 review
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Peritonitis · SSNS in children
It is very uncertain whether mycophenolate mofetil changes adverse effects: peritonitis compared with levamisole (very low certainty).
1 finding from 1 review
Abdominal pain · SSNS in children
Mycophenolate mofetil showed no clear difference in adverse effects: abdominal pain compared with levamisole (low certainty).
1 finding from 1 review
Adverse effects: anaemia · SSNS in children
It is very uncertain whether mycophenolate mofetil changes adverse effects: anaemia compared with levamisole (very low certainty).
1 finding from 1 review
Adverse effects: leukopenia · SSNS in children
It is very uncertain whether mycophenolate mofetil changes adverse effects: leukopenia compared with levamisole (very low certainty).
1 finding from 1 review
Relapse · SSNS in children
Mycophenolate mofetil showed no clear difference in relapse at 12 months compared with cyclosporin (low certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Annualised relapse rate · SSNS in children
1 finding from 1 review